Effects of repeated maternal betamethasone administration on growth and hypothalamic–pituitary–adrenal function of the ovine fetus at term

D M Sloboda¹², J P Newnham³ and J R G Challis¹²

¹Departments of Physiology and Obstetrics and Gynecology, University of Toronto, Toronto M5S 1A8, Canada
²Medical Research Council of Canada Group in Fetal and Neonatal Health and Development
³Department of Obstetrics, University of Western Australia, Perth, Australia 6008

Abstract

Synthetic glucocorticoids have become an important clinical tool with which to advance fetal lung maturation in women at risk of early preterm birth, and this has succeeded in reducing neonatal mortality and morbidity from respiratory distress syndrome. Although previous studies have shown that glucocorticoids have deleterious consequences on fetal development, there is little information regarding the effects of clinically relevant repeated maternal doses of glucocorticoids on fetal growth and hypothalamic–pituitary–adrenal (HPA) function. We hypothesised that repeated prenatal exposure to increased concentrations of glucocorticoids would alter fetal growth and HPA axis development. Pregnant ewes were injected with betamethasone (0.5 mg/kg) or vehicle at 104, 111 and 118 days of gestation (term 150 days). Animals were sacrificed at 125 and 146 days of gestation, at which time fetal weights were recorded. Maternal and fetal blood samples were gathered and fetal tissue collected. Maternal oestradiol concentrations were significantly greater than those in controls at 125 days of gestation, but were not different at 146 days. Maternal plasma progesterone concentrations were similar between groups at both 125 and 146 days of gestation. Weight at birth was significantly reduced by 23% at 125 days and 19% at 146 days of gestation (P<0.05) after exposure to glucocorticoid. Cord plasma ACTH concentrations were not significantly different between groups at day 125, but were significantly increased in day 146 fetuses of ewes that had received betamethasone (P<0.05). Cord plasma cortisol concentrations followed the same trend, although differences were not statistically significant. Cord plasma corticosteroid binding capacity (CBC) was significantly increased at 125 days of gestation in fetuses of betamethasone–treated animals (P<0.05), but not at 146 days of gestation. To examine the mechanisms regulating the increase in cord plasma ACTH of 146-day fetuses, we used in situ hybridisation to determine the distribution and levels of mRNA encoding key pituitary and hypothalamic neuropeptides of the HPA axis. In pituitaries of 146-day fetuses, there were no significant differences in the regional pattern of distribution or amounts of pro-opiomelanocortin (POMC) mRNA between betamethasone–treated animals and controls, in either the pars intermedia or the inferior and superior regions of the pars distalis. Neither prohormone convertase (PC)-1 nor PC-2 mRNA levels in pituitaries of 146-day fetuses were significantly different between treatment groups. After maternal betamethasone, immunoreactive ACTH peptide content in the fetal pars distalis was not different but glucocorticoid receptor (GR) mRNA levels in the pars distalis were increased significantly (P<0.05). No significant difference in distribution pattern or concentrations of corticotrophin-releasing hormone (CRH) mRNA, GR mRNA, oxytocin mRNA and pre-proenkephalin mRNA were found in hypothalami from fetuses at 146 days of gestation after betamethasone treatment. We conclude that antenatal betamethasone given to pregnant sheep in a manner similar to that used in human obstetric practice results in reduced weight at birth at 125 and 146 days, and altered basal cord levels of plasma ACTH and corticosteroid binding capacity, but these changes are not reflective of changes in steady state concentrations of POMC and CRH mRNA in the fetal pituitary or hypothalamus.

Journal of Endocrinology (2000) 165, 79–91

Introduction

Liggins & Howie (1972) first suggested the potential advantage of administering synthetic glucocorticoids to women at risk of early preterm birth in order to promote fetal lung maturity and prevent the development of neonatal respiratory disease. Recent practice has included repeated administration of synthetic glucocorticoids at
weekly intervals to women at risk of early preterm birth in whom delivery has not occurred. However, diagnosis of preterm birth is difficult and women not at risk may be receiving antenatal glucocorticoids unnecessarily (Ballard & Ballard 1995).

Exposure of the fetus to increased concentrations of corticosteroids may be detrimental to development. Various studies in animals have shown reductions in weight at birth (Jobe et al. 1998), alterations in organ (Johnson et al. 1981) and neuronal development (Uno et al. 1990, 1994, Dunlop et al. 1997), and increases in basal and stress-induced plasma cortisol concentrations postnatally (Uno et al. 1994) after prenatal glucocorticoids. These last observations suggest that chronic fetal exposure to glucocorticoid may alter the development of the hypothalamo–pituitary–adrenal HPA axis in utero. In the human, a reduction in birth weight and neonatal head circumference was related to an increasing number of maternal corticosteroid courses (French et al. 1999). Furthermore, an increased incidence of death from cardiovascular disease has been associated with a reduced head circumference, ponderal index and birth weight in man (Barker et al. 1993), potentially linking fetal exposure to increased glucocorticoids with increased risk of adult disease later in life.

A late gestational increase in endogenous plasma cortisol occurs in fetuses of many species and is responsible for prenatal enzyme activation within target tissues, necessary for tissue and organ maturation (Liggins 1994). The regulation of fetal HPA function and adrenal cortisol output is multifactorial. Corticotrophin–releasing hormone (CRH) and arginine vasopressin (AVP) are the primary stimulators of corticotrophs within the pars distalis of the pituitary that synthesize the polypeptide precursor, proopiomelanocortin (POMC) and secrete adrenocorticotrophic hormone (ACTH) (Antolovich et al. 1991, Yang et al. 1991). Two prohormone convertase enzymes, prohormone convertase 1 (PC1) and prohormone convertase 2 (PC2), cleave POMC to generate ACTH and related peptides (Eipper & Mains 1980). In the fetal pituitary, both the pars distalis and the pars intermedia express PC1 mRNA, whereas PC2 mRNA is highly localized to the pars intermedia (Bell et al. 1998). Other hypothalamic peptides, such as oxytocin (Kemppainen et al. 1993, Matthews 1999) and pre-proenkephalin (PENK) (Matthews & Challis 1995a), can also influence corticotroph activity. Cortisol exerts negative feedback on fetal POMC synthesis (Norman et al. 1985, McMullen et al. 1990) after binding to type 2 glucocorticoid receptors (GR) in the hypothalamus and pituitary (Yang et al. 1990, Matthews & Challis 1995b, 1997) and to hippocampal GR and type 1 mineralocorticoid receptors. Late in gestation in the fetal sheep, plasma ACTH and cortisol concentrations increase concurrently, despite the potential of negative feedback until birth occurs (Norman et al. 1985). This apparent paradox may be explained in part by correspond-

ing increases in circulating plasma corticosteroid binding globulin (CBG), the high-affinity binding protein for cortisol, which maintains a relatively low free cortisol concentration, thereby reducing the impact of cortisol negative feedback on pituitary ACTH output (Ballard et al. 1982, Berdusco et al. 1995).

Cortisol has a pivotal role in fetal growth and development and it is essential to regulate strictly the circulating glucocorticoid concentrations in the fetus. Although the effects of glucocorticoid exposure on the fetus have been well documented, very few studies have either evaluated the effects of clinically relevant glucocorticoid doses or replicated the method of glucocorticoid administration used in human obstetric practice. The long-term effects on the fetus of maternally administered glucocorticoids have not yet been ascertained. In addition, there is little information describing the mechanisms underlying either the change in fetal growth or the reported changes in fetal and neonatal endocrine function after antenatal exposure to glucocorticoid. Therefore, we determined the effects of repeated maternal glucocorticoid administration at approximately two-thirds of gestation on fetal growth and on the development of the fetal HPA axis. We hypothesized that repeated fetal exposure to glucocorticoids would decrease weight at birth and alter gene expression of key neuropeptides and receptors regulating fetal HPA function, thereby altering the fetal HPA endocrine profile.

Materials and Methods

Animals

Merino ewes were mated and singleton pregnancy was confirmed using ultrasound examination at 42 days of gestation (term 150 days). The sheep were transported to a research station at 90 days of gestation and were kept in pastures, to graze in a field environment. On the evening before injections and later delivery, sheep were brought into a nearby indoor facility.

Experimental procedures

All animals received an i.m. injection of 150 mg medroxyprogesterone acetate (Depo Provera, Upjohn, Rydalmere, NSW, Australia) at 98 days of gestation. Pregnant sheep (n=37) were allocated randomly to either control or treatment groups. Animals in the treatment group received i.m. injections of 0·5 mg/kg maternal weight betamethasone (Celestone Chronodose, Schering Plough, Baulkham Hills, NSW, Australia) at 104, 111 and 118 days of gestation. Control animals received saline injections at the same time points. The total dose of betamethasone was between 25 and 30 mg, which correlates closely with clinical doses used for fetal lung maturation in women at risk of early preterm birth (Liggins & Howie 1972). This
dose has previously been shown to improve lung function in fetal sheep (Ikegami et al. 1997). Ewes were sedated with maternal i.m. ketamine (15 mg/kg) and xylazine (0.1 mg/kg, Troy Laboratories, Smithfield, NSW, Australia) and spinal anaesthesia was induced by injection of 3–4 ml lignocaine (2%). The fetus was delivered through a midline hysterotomy and arterial blood samples were collected from the umbilical cord and from the maternal femoral vessels, after which the fetus was killed by a lethal dose of pentobarbital (30 mg/kg). Cord blood gases (PO$_2$, PCO$_2$, and pH) were measured and samples were centrifuged at 2200 g for 10 min and the plasma stored at −20 °C until required for further analysis. At 125 days of gestation, 22 animals were killed and fetal weights recorded (control n = 10; betamethasone n = 12). Tissues from 11 of these animals were collected for further analyses (control n = 5; betamethasone n = 6). At 146 days of gestation, control (n = 7) and betamethasone–treated (n = 8) animals were killed, fetal weights recorded and tissue collected for further analyses. Fetal hypothalamic blocks and pituitaries were slow frozen on dry ice for in situ hybridization and immunohistochemistry (Matthews et al. 1994). The procedures were approved by the Institutional Ethics Committees of the Western Australian Department of Agriculture and the Animal Care Committee of the University of Toronto, according to the guidelines of the Canadian Council for Animal Care.

Measurement of fetal plasma ACTH, cortisol and CBG, and maternal plasma cortisol, oestrogen and progesterone

Plasma immunoreactive (ir)-ACTH concentrations were measured using a commercial RIA kit (Incstar, Stillwater, MN, USA) previously validated for use in the fetal sheep (Norman et al. 1985). The intra-assay coefficient of variation was 15%, and the mean assay sensitivity 6.5 pg/ml. The ACTH antibody crossreacts <0.01% with α-melanocyte stimulating hormone (MSH), β-MSH, β-endorphin and β-lipotropin (LPH) (Incstar). Plasma cortisol concentrations were quantified by RIA after extraction with diethyl ether. The antibody characteristics and assay validation for measurement of cortisol in fetal sheep plasma have been described previously (Challis et al. 1981). The intra-assay coefficient of variation was 5%. Fetal plasma corticosteroid binding capacity (CBC), determined using the saturation binding assay of Ballard et al. (1982), with modifications described previously (Challis et al. 1985). The intra-assay coefficient of variation was 3%. Maternal plasma oestradiol and progesterone concentrations were quantified by RIA after extraction with diethyl ether. The antibody characteristics and assay validation for measurements in the sheep have been described previously (Challis et al. 1981). The intra-assay coefficient of variation was 15%. For each hormone and CBC, all samples were analysed in a single assay.

Pituitary ACTH content

The pars distalis was separated from the pars intermedia in those frozen 146-day pituitaries that remained after cryosectioning for in situ hybridisation. Each pars distalis was weighed and homogenised (PT200 Homogeniser, Polytron, Kinematica AG, Switzerland) in extraction buffer (1 M HCl, 5% v/v formic acid, 1% w/v NaCl, 1% v/v trifluoroacetic acid) (Bennett et al. 1981). Samples were centrifuged at 1775 g for 10 min at 4 °C. ir-ACTH concentrations were analysed using a commercial RIA (Incstar). Protein content was determined using the method of Bradford (1976) and ACTH(1–39) concentrations were expressed per mg of protein. Intra-assay coefficient of variation for the ACTH assay was 8%, and all samples were analysed in a single assay.

In situ hybridisation of 146-day fetal pituitary POMC, PC1 and PC2 mRNA and hypothalamic CRH, GR, AVP, oxytocin and PENK mRNA

The method for in situ hybridisation has been described previously in detail (Matthews et al. 1991, 1994). Briefly, frozen pituitaries and hypothalami of the 146-day fetal group were sectioned (12 μm coronal sections) using a cryostat (Tissue-Tek, Miles Canada, Etobicoke, Canada) and mounted onto poly-L-lysine (Sigma Chemical, St Louis, MO, USA)-coated slides, dried and fixed in 4% paraformaldehyde for 5 min, rinsed in PBS (2 × 1 min), dehydrated in an alcohol series and stored in 95% alcohol at 4 °C until required for hybridisation. Pituitary sections were incubated with α-35S-labelled, 45-mer oligonucleotide antisense probes. In the pituitary, antisense probes were complementary to bases 711–756 of the porcine POMC gene (Gossard et al. 1981), bases 231–275 of the porcine PC1 gene (Dai et al. 1995), bases 153–197 of the porcine PC2 gene (Seidah et al. 1992), and bases 146–191 of the ovine GR gene (Yang et al. 1992). Hypothalamic sections were incubated with α-35S-labelled, 45-mer oligonucleotide antisense probes complementary to bases 503–547 of the ovine CRH gene (Matthews et al. 1991), bases 146–191 of the GR gene (Yang et al. 1992), bases 1–45 of the bovine PENK gene (Noda et al. 1982), and to bases 771–816 of the ovine oxytocin–neurophysin gene (Ivell et al. 1990). All probes have been characterised and used previously (Matthews et al. 1991, 1993, Broad et al. 1993, Matthews & Challis 1995a, Jeffray et al. 1998). Control slides were incubated with α-35S-labelled, 45-mer oligonucleotide random sequences, which did not correspond to the antisense probes. All slides were exposed together with 14C standards (American Radiochemical, St Louis, MO, USA) to ensure analysis within the linear range of the autoradiographic film (Biomax, Kodak). The relative optical density (ROD) of the signal on the film of 9–14 sections per tissue was quantified using a computerised image
Effects of prenatal betamethasone exposure

Effects of prenatal betamethasone exposure on concentrations of maternal plasma oestradiol, progesterone and cortisol, and CBC

Maternal plasma oestradiol and progesterone were measured in order to evaluate whether maternal exposure to betamethasone induced the pattern of increase in circulating oestradiol and decrease in progesterone seen with onset of spontaneous and induced parturition in sheep (Liggins et al. 1973). Maternal plasma oestradiol concentrations were significantly greater after betamethasone treatment at 125 days of gestation, 1 week after the final betamethasone injection ($P<0.05$; Table 1), but were not significantly different from controls at 146 days of gestation. Maternal plasma progesterone concentrations were similar between groups (Table 1). Neither maternal mean plasma cortisol concentration nor CBC was altered significantly after maternal exposure to betamethasone (Table 1).

**Cord blood gases and pH**

Fetal status at the time of delivery was assessed by measurement of cord blood pH and blood gas measurements. Mean cord arterial $PO_2$, $PCO_2$ and pH were similar in both groups (125 and 146 days of gestation) after betamethasone treatment (Table 2).

**Effect of prenatal betamethasone exposure on weight at birth**

Fetal weight at 125 days of gestation after repeated exposure to betamethasone in utero was significantly reduced, by 23% ($P<0.05$; Table 2). At 146 days of gestation, 30 days after the last course of betamethasone, fetal weight was reduced significantly, by 19%, compared with that of controls ($P<0.05$; Table 2).

### Table 1 Maternal arterial oestradiol, progesterone and cortisol concentrations, and CBC at 125 and 146 days of gestation after administration of either saline or betamethasone.

<table>
<thead>
<tr>
<th></th>
<th>125 days of gestation</th>
<th>146 days of gestation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control ($n=5$)</td>
<td>Betamethasone ($n=6$)</td>
</tr>
<tr>
<td>Oestradiol (pg/ml)</td>
<td>11.1 ± 7.3</td>
<td>58.0 ± 10.2*</td>
</tr>
<tr>
<td>Progesterone (ng/ml)</td>
<td>9.8 ± 2.4</td>
<td>42 ± 0.5</td>
</tr>
<tr>
<td>Cortisol (ng/ml)</td>
<td>16.7 ± 4.2</td>
<td>7.3 ± 2.6</td>
</tr>
<tr>
<td>CBC (ng/ml)</td>
<td>10.9 ± 0.03</td>
<td>10.4 ± 0.2</td>
</tr>
</tbody>
</table>

* $P<0.05$ compared with control.
Table 2 Cord plasma pH, PO$_2$, PCO$_2$ and fetal weight at 125 and 146 days of gestation after prenatal exposure to either saline or betamethasone. Values are mean ± S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>125 days of gestation</th>
<th>146 days of gestation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=5) †</td>
<td>Betamethasone (n=6) ‡</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.32 ± 0.03</td>
<td>7.41 ± 0.02</td>
</tr>
<tr>
<td>PO$_2$ (mmHg)</td>
<td>9.1 ± 1.0</td>
<td>10.4 ± 1.1</td>
</tr>
<tr>
<td>PCO$_2$ (mmHg)</td>
<td>54.3 ± 2.0</td>
<td>51.4 ± 1.9</td>
</tr>
<tr>
<td>Fetal weight (kg)</td>
<td>2.7 ± 0.5</td>
<td>2.1 ± 0.3*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.31 ± 0.02</td>
<td>7.33 ± 0.03</td>
</tr>
<tr>
<td></td>
<td>11.4 ± 1.2</td>
<td>10.0 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>52.9 ± 2.7</td>
<td>51.1 ± 2.2</td>
</tr>
<tr>
<td></td>
<td>46.6 ± 0.3</td>
<td>3.8 ± 0.2*</td>
</tr>
</tbody>
</table>

For fetal weight measurements: †n=10; ‡n=12 (see Methods).

*P<0.05 compared with control.

Table 3 Cord plasma cortisol and ACTH concentrations, and CBC, at 125 and 146 days of gestation, after prenatal exposure to either saline or betamethasone. Values are mean ± S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>125 days of gestation</th>
<th>146 days of gestation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=5)</td>
<td>Betamethasone (n=6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTH (pg/ml)</td>
<td>29.5 ± 3.0</td>
<td>36.0 ± 10.1</td>
</tr>
<tr>
<td>Cortisol (ng/ml)</td>
<td>3.2 ± 0.6</td>
<td>1.9 ± 0.3</td>
</tr>
<tr>
<td>CBC (ng/ml)</td>
<td>17.3 ± 3.2</td>
<td>47.9 ± 10.7*</td>
</tr>
<tr>
<td></td>
<td>54.6 ± 5.2</td>
<td>82.1 ± 6.7*</td>
</tr>
<tr>
<td></td>
<td>12.5 ± 2.2</td>
<td>35.7 ± 17.8</td>
</tr>
<tr>
<td></td>
<td>57.3 ± 17.7</td>
<td>54.3 ± 14.4</td>
</tr>
</tbody>
</table>

*P<0.05 compared with control.

Basal cord plasma ir-ACTH, cortisol and CBG concentrations

At 125 days of gestation, mean cord plasma ir-ACTH concentrations were not significantly different from those in controls after repeated exposure to glucocorticoid (Table 3). At 146 days, however, cord plasma ir-ACTH concentrations were significantly greater in betamethasone-treated fetuses (P<0.05; Table 3). Mean cord plasma cortisol concentrations at 125 days of gestation were not altered after glucocorticoid exposure and, although cord plasma cortisol concentrations at 146 days tended to be greater than those in controls, these differences did not reach statistical significance (Table 3). Plasma CBG concentration, measured as CBC, was significantly greater at 125 days of gestation after prenatal exposure to betamethasone (P<0.05; Table 3). This difference was not present, however, at 146 days of gestation.

Effect of prenatal betamethasone exposure on pituitary ir-ACTH peptide content at 146 days of gestation

In order to evaluate the mechanisms underlying the increase in cord ACTH concentrations at term, we determined the ir-ACTH(1–39) peptide content in pituitary tissue, in addition to conducting immunohistochemical localisation of ir-ACTH. Positive ir-ACTH staining was observed in both the pars distalis and the pars intermedia, after betamethasone exposure, in tissue from fetuses at 146 days of gestation (Fig. 1A, B). Tissue sections from betamethasone-treated fetuses showed less staining for ir-ACTH in the pars distalis but similar ir-ACTH in the pars intermedia (Fig. 1A, B). Adjacent sections incubated with antibody preabsorbed with an excess of human ACTH(1–24) showed no positive staining for ir-ACTH (Fig. 1C). In order to quantify changes in pituitary ACTH content, protein was extracted from the pars distalis and analysed for ir-ACTH. Concentrations of pars distalis ir-ACTH (pg/mg protein) in the betamethasone-treated animals were not statistically different from those in controls (controls: 7.6 ± 1.2 pg/mg, n=7; betamethasone: 5.0 ± 0.8 pg/mg, n=8; P=0.09).

Effect of prenatal betamethasone exposure on levels of pituitary POMC, PC1, PC2 and GR mRNA at 146 days of gestation

POMC mRNA distribution was not altered by prenatal exposure to betamethasone exposure (Fig. 2A, B) and was similar to that seen previously in fetal sheep at this time in gestation (Matthews et al. 1994). Pituitary levels of POMC mRNA were significantly greater in the inferior region of the pars distalis than in the superior region, in both control
and betamethasone-treated groups (P<0.05), but were not significantly different between treatment groups (Fig. 3C). Neither PC1 nor PC2 mRNA levels or distribution were altered after betamethasone exposure (Fig. 2C–F). Maternal betamethasone administration increased GR mRNA levels significantly in the pars distalis of 146-day fetal pituitaries (Fig. 2G, H, Fig. 4; P<0.05). GR mRNA was not detected in the pars intermedia.

**Effect of prenatal betamethasone exposure on hypothalamic CRH, GR, oxytocin, and PENK mRNA at 146 days of gestation**

The distribution of CRH, GR (Fig. 5A–D), oxytocin and PENK mRNA (data not shown) in the paraventricular nucleus of 146 day fetal hypothalami was not altered by prenatal exposure to betamethasone. Levels of CRH and GR mRNA, as determined by computerised image analysis were similar in both groups (Fig. 5F, G). Levels of oxytocin and PENK mRNA were also similar in both groups after maternal betamethasone administration (data not shown).

**Discussion**

We have demonstrated that clinically relevant maternal administration of betamethasone in pregnant sheep at mid-gestation results in significant reductions in weight at birth. Repeated fetal glucocorticoid exposure at that time of gestation resulted in significant increases in basal cord plasma CBC at 125 days of gestation and significant increases in basal ACTH concentrations at 146 days of gestation. Plasma cortisol concentrations showed a trend similar to that in ACTH values, but the differences did not reach statistical significance. It appears that these changes were not associated with detectable alterations in the levels of mRNA encoding key neuropeptides of the HPA axis in either the fetal pituitary or the hypothalamus.

The increase in cord plasma ACTH is unlikely to be related to the onset of labour, as maternal oestradiol and progesterone concentrations were not significantly different between the groups at 146 days of gestation, and neither group exhibited the pattern of maternal oestradiol or progesterone change characteristic of parturition. Maternal oestradiol concentrations were increased at day 125, closer to the time of betamethasone administration, reproducing the changes reported by Liggins et al. (1973) after fetal glucocorticoid treatment. We cannot exclude the possibility that betamethasone stimulated prostaglandin production in the fetal placenta (Challis et al. 1999), and that an increase in fetal circulating prostaglandins stimulated an increase in fetal ACTH secretion (Louis et al. 1976, Ratter et al. 1979). We did not, however, collect fetal blood samples in a manner appropriate to measure fetal prostaglandin E2.

We reasoned, therefore, that the increase in cord plasma ACTH was the result of functional changes in the fetal HPA axis after exposure to increased glucocorticoids. Increased cord plasma ACTH concentrations at 146 days of gestation in this study were not accompanied by

---

**Figure 1** Photographs of immunohistochemical staining of ACTH in the pars distalis (PD) and the pars intermedia (PI) of saline- (A) and betamethasone- (B) treated animals at 146 days of gestation. (C) Preabsorption control. PN, pars nervosa. Scale bar represents 50 μm.
Figure 2 Localisation of POMC (A, B), PC1 (C, D), PC2 (E, F), and GR (G, H) mRNA in the pars distalis (PD) and pars intermedia (PI) of 146-day fetal pituitaries after in situ hybridisation of coronal sections with 35S-labelled oligonucleotide probes, after administration of either saline or betamethasone. Images are colour-enhanced and scales represent relative intensity of signal. Control sections were incubated with random nonsense sequences and showed no signal; a representative example is shown in I. SUP, superior region; INF, inferior region.
significant changes in precursor POMC mRNA levels in either the pars intermedia or the pars distalis. Therefore the term increase in basal ACTH concentrations is probably not a result of increased transcription, although we did not evaluate mRNA stability or transcriptional activity. It remains possible that small changes in steady-state POMC mRNA were present, but these differences could not be detected by in situ hybridization. The relative distribution of PC1 and PC2 mRNA levels within the pituitary was consistent with that reported in other studies (Marcinkiewicz et al. 1994, Bell et al. 1998). However, we did not measure prohormone convertase enzymatic activity, and PC1 and PC2 are not localised solely to the corticotrophs in the pars distalis, therefore we cannot firmly conclude that POMC processing is unaffected by exposure to glucocorticoid.

Positive ir-ACTH staining in the cells of the pars intermedia of 146-day pituitaries of fetuses treated with betamethasone was similar to that of control pituitaries. Less staining was observed, however, in the pars distalis of treated pituitaries. These observations are consistent with those of Jeffray et al. (1998), who reported a decrease in the number of ir-ACTH-positive corticotrophs in the fetal pars distalis after 96 h of fetal cortisol infusion, but no change in the pars intermedia. Content of ACTH(1–39) in the pars distalis was similar in 146-day fetuses of both groups. It remains possible that other sites of POMC production, such as the lung or placenta, may contribute to the increase in cord plasma ACTH (Cudd & Wood 1995, Jeffray et al. 1999), after antenatal glucocorticoid treatment – effects that could be mediated by placental CRH (Jones et al. 1989).

Negative feedback is an important regulator of cortisol synthesis and secretion in the fetal HPA axis, through glucocorticoid binding to type II receptors (GR) in the PVN and in the pars distalis to reduce CRH and POMC production. The exact role of GRs in the pituitary, however, remains unclear. In the fetal sheep, GR mRNA and protein levels in the pars distalis increase at term (Yang et al. 1990, Matthews et al. 1995). There are no studies that have evaluated the effect of repeated maternal betamethasone administration on pituitary or hypothalamic GR mRNA levels, receptor number or activity in the fetal sheep. The increase in GR mRNA levels that we observed in the pars distalis of fetuses at day 146 of gestation after betamethasone treatment is consistent with the increase in pituitary GR seen at term as endogenous cortisol increases (Yang et al. 1990, 1992). This change may contribute to the effect of cortisol in promoting an increased output of ACTH(1–39) relative to large-molecular-weight POMC peptides by corticotrophs treated concurrently with CRH in vitro (Durand et al. 1986). Although mean cord cortisol concentrations in
Effects of prenatal betamethasone exposure  
D M SLOBODA and others

Figure 4 Bar graph illustrating densitometric analysis of GR mRNA levels in coronal sections of the entire pars distalis of 146-day fetal pituitaries after administration of either saline (■) or betamethasone (□). Values are presented as relative optical density (ROD) and are mean ± S.E.M. *P<0·05.

CBG late in gestation maintains low concentrations of circulating cortisol and therefore maintains low negative feedback on the pituitary and the hypothalamus (Ballard et al. 1982, Berdusco et al. 1994, 1995). Glucocorticoids have been shown to increase plasma CBG and hepatic CBG mRNA in fetal sheep (Berdusco et al. 1994). We suggest therefore, that repeated fetal exposure to betamethasone between days 104 and 118 resulted in an increase in CBG production and an increase in plasma CBG measured at 125 days of gestation. In turn, CBG binds circulating cortisol, resulting in a decrease in negative feedback at the level of the hypothalamus/pituitary and an increase in ACTH secretion that persists through later gestation, even though CBG concentrations have been restored to control values. In effect, maternal betamethasone alters the set point(s) of the fetal HPA negative feedback.

Our results are consistent with others that have shown changes in fetal or newborn circulating ACTH and cortisol concentrations following in utero exposure to betamethasone (Uno et al. 1994). Uno et al. (1990) found that the offspring of pregnant rhesus monkeys exposed to supra-pharmacological doses of betamethasone showed increases in both basal and stimulated concentrations of ACTH and cortisol at 10 months of age compared with controls (Uno et al. 1990). Recent data in humans also link reductions in fetal growth with alterations in circulating glucocorticoids (Phillips et al. 1998). It has been reported that fasting plasma cortisol concentrations in 64-year-old men were inversely related to their birth weight, and that increased plasma cortisol concentrations were significantly associated with an increase in blood pressure, plasma glucose and insulin resistance (Phillips et al. 1998). These data support the hypothesis that an adverse intrauterine environment can permanently reset the developing fetal HPA axis, leading to an increased risk of adult diseases. It is possible that precocious exposure of the fetus to glucocorticoids creates an adverse intrauterine environment within which this may occur.

Exposure to glucocorticoid results in reductions in weight at birth (Reinisch et al. 1978, Johnson et al. 1981, Jobe et al. 1998) – a finding that we have substantiated using smaller amounts of steroid in the present study. Organ weights from a larger cohort of animals treated alongside this group have been published elsewhere and showed reductions in liver, brain and kidney weight and a significant increase in the brain: liver weight ratio (Newnham et al. 1999). Treatment of pregnant rhesus monkeys with betamethasone resulted in reductions in fetal brain, liver, pancreas, heart and adrenal weights at term (Johnson et al. 1981). A recent report by French et al. (1999) provides clear evidence that decreased birth weight ratios of singleton infants of mothers treated with prenatal glucocorticoids are associated with the number of glucocorticoid courses: head circumference analyses showed significant reductions when the mother had received more

betamethasone-treated animals at term were threefold greater than those in controls, consistent with ACTH patterns, there was variability between individual animals and the cortisol values were not statistically different between groups. Thus we did not find significant increases in either cord cortisol or pituitary GR mRNA after betamethasone treatment.

Our data suggest that increases in cord plasma ACTH are not associated with changes in mRNA levels of hypothalamic neuropeptides. Matthews et al. (1995) reported that fetal cortisol infusion late in gestation did not alter basal CRH or AVP mRNA levels, but did suppress hypoxaemia-induced increases in CRH mRNA levels (Matthews & Challis 1995b). Therefore glucocorticoids have differential effects on basal and stimulated levels of CRH mRNA. Our data also suggest that it is unlikely that increases in cord plasma ACTH are the result of changes in steady-state expression of oxytocin or PENK. A substantial body of evidence exists to suggest that fetal exposure to glucocorticoid results in changes in hippocampal GR and mineralocorticoid receptors (Meaney & Aitken 1985, Sapolsky et al. 1990, Uno et al. 1994). In the present study, if such changes did occur, they did not result in detectable alterations in levels of mRNA encoding key hypothalamic neuropeptides or pituitary POMC. Nevertheless, such measurements will be of interest in the context of long-term programming of HPA function by antenatal corticosteroids.

Plasma CBC was significantly increased at 125 days of gestation after betamethasone treatment. It has been suggested previously that an increase in fetal plasma
Figure 5 Localisation of CRH (A, B), and GR (C, D) mRNA in the PVN of 146-day fetal hypothalami after *in situ* hybridisation of coronal sections with ^35^S-labelled oligonucleotide probes, after administration of either saline or betamethasone. Images are colour-enhanced and scales represent relative intensity of signal. Control sections were incubated with random nonsense sequences and showed no signal; a representative example is shown in E. The bar graph illustrates the results of densitometric analysis of CRH (F) and GR (G) mRNA levels in coronal sections of the entire PVN of 146-day fetal hypothalami after administration of either saline (■) or betamethasone (□). Values are presented as relative optical density (ROD) and are mean ± S.E.M.
than one glucocorticoid course (French et al. 1999). The mechanisms altering fetal growth, however, remain unknown. Insulin-like growth factors (IGFs) are generally believed to influence fetal growth by stimulating cell proliferation (D’Ercole 1987), and it has been proposed that an increase in endogenous fetal glucocorticoids regulates IGF-II mRNA expression and thereby regulates fetal growth, especially later in gestation (Li et al. 1993). It is possible that the reduction in fetal growth after repeated exposure to betamethasone in this study may be mediated through a reduction in tissue-specific IGF-II expression. Further studies are required to investigate this possibility fully. We suggest, however, that maternal administration of betamethasone between days 104 and 118 resulted in a shift in the fetal growth trajectory to a parallel but lower profile, resulting in similar differences in weight between treated animals and controls at term, as at day 125 of gestation. This is the first study to evaluate levels of mRNA encoding the key pituitary and hypothalamic neuropeptides that regulate the fetal HPA axis after repeated fetal exposure to clinically relevant doses of glucocorticoids. We suggest that repeated maternal administration of betamethasone may produce long-term changes in growth and the development of the fetal HPA axis. We speculate that these observations raise the possibility that corticosteroids administered during the course of pregnancy to promote maturational changes in the fetus may have adverse consequences on both short-term and long-term fetal development.

Acknowledgements

We thank Professors Stephen G Matthews and Alan Jobe for their interest in these studies. This work was supported by the Medical Research Council of Canada (MRC Group in Fetal and Neonatal Health and Development) and the Women and Infants Research Foundation at King Edward Memorial Hospital and the NHMRC of Australia (Project Grant 981406).

References


Berdusco ETM, Milne WK & Challis JRG 1994 Low-dose cortisol infusion increases plasma corticosteroid-binding globulin (CBG) and the amount of hepatic CBG mRNA in fetal sheep on day 100 of gestation. Journal of Endocrinology 140 425–430.


Eipper BA & Mains RE 1980 Structure and biosynthesis of pro-adenocorticotrophin/endorphin and related peptides. Endocrine Reviews 1 1–27.


Ikegami M, Jobe AH, Newnham J, Polk DH, Willet KE & Sly P 1997 Repetitive prenatal glucocorticoids improve lung function and


Received 2 July 1999
Revised manuscript received 28 October 1999
Accepted 9 November 1999